Pharmaceutical Industry Market Research & Statistics

Global Pharmaceutical Industry

 

The global pharmaceutical industry is expected to be worth more than $1 trillion in 2014, marking a 5% compound annual growth rate according to research from Urch Publishing.

 

The industry is comprised of companies that make, patent and sell drugs that have therapeutic effect. The market is highly competitive and entry is difficult due to a combination of strict regulations and the need for extensive research and development, involving time-consuming clinical trials.

 

In addition, high research and development costs, lengthy clinical trial processes, expiring patents and difficulty in gaining product approval from the appropriate regulatory bodies all mean that companies must produce blockbuster drugs and continue to do so to remain in good standing.

 

Other challenges facing the industry include pressure from purchasers, such as hospitals, who negotiate discounts with wholesalers or manufacturers when buying in bulk – thereby increasing pressure on pharmaceutical companies to produce cost-effective drugs to remain competitive and gain approval for new drugs. According to the Center for Drug Evaluation and Research, on average there have been less than 23 approvals annually over the past decade. Industry observer Pharmalot states there was a fall in the number of applications for approval received by the US Food and Drug Administration from just fewer than 40 in 2009 to 23 in 2010.

 

Though patents protect the intellectual property rights of specific drugs, usually for approximately 20 years, pharmaceutical companies face increasing pressure related to generics, which are drugs comprised of the same ingredients as patented drugs but sold under a drug’s chemical name rather than the pharmaceutical brand name.

 

Medical professionals can prescribe drugs under their chemical name without specifying a brand. The pharmaceutical market spans a spectrum of drugs and medication, including prescription, generic and over-the-counter drugs. The scope also includes drug delivery technology, drug discovery and development, vitamins and supplements, pathology, therapeutics, and pharmacies and drug stores.

 

More »

Talk to Sam

+1 718 473 0872

Search inside this page

All regions

You might be interested in: drug, vaccine, medicine, more »

Download Unlimited Documents from Trusted Public Sources

Global & Regional

Global Pharmaceutical Industry Analysis

  • Pharma Market Insight & Strategy

« Between 2008 and 2012, generics contributed to 45 % of the sales growth in value, compared to 40% for biotech and non biotech branded ethicals. »

  • January 2012
    20 pages
  • Pharmaceutical  

    Generic Drug  

  • United States  

    India  

    World  

View report >

Global - Europe Pharmaceuticals Market Profile

  • The Pharmaceutical Industry in Figures

« The research-based pharmaceutical industry can play a critical role in restoring Europe to growth and ensuring future competitiveness in an advancing global economy. In 2012 it invested an estimated € 30,000 million in R&D in Europe. »

  • January 2012
    28 pages
  • Drug And Medica...  

    Medicine  

    Research And De...  

  • Europe  

    Switzerland  

    World  

View report >

Global - Europe - Germany Pharmaceuticals Market Analysis

« The pharmaceutical companies include medium-sized companies, as well as companies under owner-management and German branches of multinational corporations. Furthemore, biotechnology companies are to be considered. These companies primarily develop and / or produce pharmaceutical drugs ans diagnostic products, and are partially included in the 899 companies mentioned above. It is still true that nearly 95% of companies manufacturing pharmaceutical drugs in Germany employ less than 500 staff. »

  • January 2012
    88 pages
  • Drug  

    Health Care Sys...  

    Pharmacy  

  • Germany  

    Europe  

    World  

View report >

Pharmerging Markets

  • Global Pharma Market Outlook - with Focus on Emerging Markets

« Global spending on drugs will reach more than $1.2 trillion by 2017 with a rising growth rate. IMS Health increases Pharmerging countries to 21 as healthcare improvement becomes global priority. »

  • January 2013
    22 pages
  • Pharmaceutical  

    Healthcare  

  • World  

    Europe  

    Brazil  

View report >

APEC & Philippines Pharma Markets

  • Pharmaceutical Market Perspective

« The Philippine pharma market at 131 bn, grew 2.6%in 4Q12, following 3 yrs of single-digit growth trends. Less Nutrition products, the total pharma market is at 124 bn in 4Q12, growing slower vs. previous period at 2.8%. »

  • July 2013
    29 pages
  • Generic Drug  

    Generics  

  • Philippines  

    World  

    Asia  

View report >

Asia Pharma Markets

  • Ims Asia-pacific

« Throughout 2012 we were enthused by trends suggesting that the pharmaceutical market in Asia will likely reach USD $350 billion in 2016, comprising 30% of the global pharmaceutical market and driving close to 50% of global, incremental growth through 2016. »

  • January 2012
    28 pages
  • Pharmaceutical  

  • Asia  

    World  

View report >

Strategy & Trends

Pharma Trends - Switch from Prescription Drugs to OTC

  • Otc Vs. Prescrip.on Drugs Market Study & Trends

« The compound annual growth rate (CAGR) of market from 2005-2009 was 3.3%. The CAGR from 2009-2014 is expected to be 2.7 % »

  • January 2009
    47 pages
  • Drug  

View report >

Generics and Biosimilars Market Dynamics

  • The Pharmaceutical Market Adapting to Decreased Public Expenditu...

« Across 7 key therapy areas in Europe, the average price per treatment day has decreased 60%, while number of treatment days has increased nearly 200% over 12 years . »

  • January 2012
    25 pages
  • Generic Drug  

    Generics  

  • Europe  

    Germany  

    Greece  

View report >

Japan R&D Pipeline Drugs Analysis

  • Trends in the Japanese Pharma R&d Industry: from Clinical Trials...

« Total global pipeline size – key facts : - Number of active drugs stands at 10,479 , 0.3% increase, in contrast to 7.6% seen in 2012 , - Increases from 2011-2012 sustained , - ~10,500 the new norm »

  • May 2013
    65 pages
  • R&d  

    Drug  

  • Japan  

    Asia  

    World  

View report >

Pharmerging Market Access

  • Pharma Emerging Markets 2.0

« The pharmaceutical industry is undergoing dramatic change. Pricing pressures, pipeline challenges, and emerging global markets are reshaping the way these companies operate. Providers to the pharmaceutical industry, such as contract manufacturers, will need to transform as well. In the year to come, contract manufacturers that differentiate their offerings and capabilities will be able to retain customers and grow their business within this highly competitive marketplace. »

  • January 2012
    44 pages
  • Pharmaceutical  

  • Africa  

    World  

View report >

Pharma Trends - Contract Manufacturing

  • 2014 Contract Manufacturingtrends

« Highlights : - Drug products on the shortages list are highly concentrated: 63% are in five disease areas: oncology, anti-infectives, cardiovascular, central nervous system and pain management , - over 80% are generic injectables , - only 6.5% are controlled substances , - cancer drugs account for 28 of the 168 products, affecting nearly 550,000 patients annually. The shortage problem affects drug products of all ages. Half came to the market before 1990. 25% were introduced to the market since 2000. »

  • January 2014
    6 pages
  • Pharmaceutical  

  • World  

View report >

US Drug Shortage

  • Drug Shortages: a Closer Look at Products, Suppliers and Volume ...

« Drug products on the shortages list are highly concentrated: 63% are in five disease areas: oncology, anti-infectives, cardiovascular, central nervous system and pain management. Over 80% are generic injectables. Only 6.5% are controlled substances. Cancer drugs account for 28 of the 168 products, affecting nearly 550,000 patients annually. The shortage problem affects drug products of all ages. • Half came to the market before 1990. 25% were introduced to the market since 2000. »

  • November 2011
    38 pages
  • Drug  

  • United States  

View report >

Main Countries

US Pharmaceutical Market

  • The us Pharmaceutical Market

« Spending on branded drugs totaled $235Bn, and increased by 2.1%, while spending on unbranded generics increased 13.8% and branded generics by 2.8%. Spending on traditional or non-specialty medicines grew by 2.0%, while those specialty medicines grew by 8.8%. Small molecule spending totaled $250Bn, an increase of 2.9% as biologics grew by 6.0%, amounting to $69Bn. Spending on drugs through retail channels increased by 3.6%, while institutional channels rose by 3.7%. Oral forms of medicines rose by 1.5%,while spending on injectables increased by 6.2%. »

  • October 2012
    75 pages
  • Medicine  

  • United States  

View report >

US Drug Distributors Markets

  • Six Trends in Pharmaceutical Distribution

« URCH Publishing and IMS Health value the pharmaceutical market is valued at $837B in 2010 and estimated 2011 at $897B for 2011 while employing over 4M people. »

  • January 2011
    28 pages
  • Drug  

  • World  

View report >

Japan Pharmaceutical Markets

  • Global Pharmaceutical & Biotechnology

« ¥ 160b (JPY) Biologics market is going to open by 2015 in Japan. JP regulators are half way through compared to US and EU in drafting the biosimilar guideline. As batch to batch biologic variation is high, JP regulators are not willing to accept import of biogenerics/biosimilars from outside and hence we expect this opportunity to be exploited locally. Currently ~3 biogenerics’s are available i.e. Somatropin BS by Sandoz and Epoetin alfa. Recent development in biogeneric space by the local generic companies is indicative of JP companies’ interest to exploit these biogenerics opportunities. »

  • January 2013
    49 pages
  • Drug  

  • World  

    Japan  

    United States  

View report >

China Drugs Market Access

  • New Rules for Winning in China's Pharmaceutical Market

« The rules of the game are being rewritten in the pharmaceutical market in China. Some basic truths about the Chinese pharmaceutical market will remain unaltered, including the fact that it is a large, vitally important market that boasts robust growth prospects –but little else will remain stratic. In fact, the Chinese pharmaceutical market is in the midst of a fundamental shift that will dramatically alter the winning strategies of both multinational corporations (MNCs) and local companies. »

  • January 2011
    19 pages
  • Drug And Medica...  

    Drug  

  • China  

View report >

Brazil Pharmaceutical Markets

  • Pharmaceutical Market Indicators

« Brazil Pharmaceutical Market : Participation Percentage of Pharmaceutical Products Exports vs. Brazil's Total Exports: in 2013: 0.62 %, in 2012: 0.62%, in 2011 : 0.57%, in 2010 : 0.70%, in 2008: 0.49%. »

  • July 2013
    16 pages
  • Pharmaceutical  

  • Brazil  

    United States  

    South America  

View report >

India Pharmaceutical Industry

« The country’s pharma industry accounts for about 1.4 per cent of the global pharma industry in value terms and 10 per cent in volume terms. The Indian pharmaceutical industry revenue is expected to expand at a CAGR of 17.8 per cent during 2008–16 and reach USD36 billion. The healthcare sector in India is expected to reach USD100 billion by 2015 from the current USD65 billion. The generics market is expected to grow to USD26.1 billion by 2016 from current USD11.3 billion in 2011, India’s generics market has immense potential for growth. »

  • January 2013
    45 pages
  • Drug And Medica...  

    Drug  

  • India  

    Asia  

View report >

Russia Pharma Market

  • Russian Pharma: Road Map

« Growth of the pharmaceutical market has stabilized: 12% in 2012, 12% in 2011, 6% in 2010, 17% in 2009, 24% in 2008, 11% in 2007. »

  • May 2013
    16 pages
  • Drug And Medica...  

    Drug  

    Medicine  

  • Europe  

    Russian Federat...  

View report >

Key players

Johnson & Johnson Company Profile

  • 1st Quarter 2014 Earnings call Presentation

« Johnson & Johnson : 1st Quarter 2014 Sales by Geographic Area : - US: $8.2 US Billions in 1Q 2014,Europe: 4.9, Western Hemisphere (ex U.S.): 1.7, Asia-Pacific, Africa : 3.3, International: 9.9, Worldwide: $18.1. »

  • January 2014
    14 pages
  • Pharmaceutical  

  • United States  

View report >

Pfizer Company Information

  • Innovating within the Pharmaceutical Industry

« Pfizer Today: $59 billion revenue in 2012, 58 manufacturing sites worldwide, 175 markets in which Pfizer sells product, 10 products with sales greater than $1 billion 2012, 260 R&D partner institutions across the globe, $3.1 billion cash and products donated from U.S. and Puerto Rico in 2011 globally, First Primary care and specialty care businesses worldwide, over 90,000 colleagues around the world. »

  • June 2013
    53 pages
  • R&d  

  • World  

View report >

Novartis Company Profile

  • Novartis Investor Day

« Throughout our history, we have very actively managed our portfolio. Novartis’ total shareholder return has exceeded competitors’. We’re now moving into a phase of sharpening our strategy and our portfolio. »

  • November 2013
    184 pages
  • Cancer  

    Oncology  

  • United States  

    World  

View report >

Roche Company Profile

  • Roche in Brief

« Roche delivered a 22% increase in IFRS net income and the Board of Directors will propose a 6% increase in dividend to CHF 7.80. Roche signed agreements with 160 partners, across a multitude of areas, including immunotherapy for cancer and antibiotics for multi-resistant bacteria. »

  • January 2014
    32 pages
  • Pharmaceutical  

View report >

Roche Company R&D Strategy

  • Committed to Innovation and Growth

« 2012 Roche Highlights : On track for full year targets, Strong pipeline : > 70 New Molecular Entities in clinical development, • 11 out of 14 late stage trials positive, Newsflow supporting long-term growth: - Perjeta and T-DM1 with significant OS benefit vs. Standard of Care, -Actemra head to head vs. Humira (ADACTA), - Avastin TML in mCRC filed in US and EU, - Hematology early stage pipeline (MabThera /Rituxan successors) maturing »

  • January 2012
    24 pages
  • Pharmaceutical  

  • China  

View report >

Sanofi Development in China

  • Exane Bnp Paribas Healthcare Conference

« From Sep to Dec 2013, the underlying growth profile of the new Sanofi emerged Throughout 2013, we left the patent cliff further behind us and took decisive action to resolve temporary operational challenges Growth platforms now account for 73% of sales compared to 43% in 2008 Sanofi has currently 9 high-potential late-stage projects 45% of sales come from biologics and 80% of development pipeline projects are biologics. »

  • January 2013
    32 pages
  • Pathology  

    Diabete  

    Medical Facilit...  

  • China  

    Asia  

View report >

About 26 000 reports

Purchase Reports From Reputable Market Research Publishers
(From $ 55 - $ 21 113)

Vitamin and Provitamin Markets in the World to 2018 - Market Size, Trends, and Forecasts

Vitamin and Provitamin Markets in the World to 2018 - Market Size, Trends, and Forecasts

  • $ 22 464
  • Industry report
  • May 2014
  • by Global Research & Data Services

The expansion of the global vitamin and provitamin industry is forecast to reach 2.6% p.a. in the coming years. Between 2007 and 2013 the market increased with an average annual growth of 8.0%. Currently, ...

Oncology Drug Pathway Analyzer (premium Version)

July 2014 $ 14 850

Vitamin And Provitamin Markets In Europe To 2018 - Mark ...

May 2014 $ 12 356

Pharmapoint: Non-small Cell Lung Cancer - Global Drug F ...

April 2014 $ 9 995

Adalimumab - Comprehensive Patent Search

July 2014 $ 10 118

Amphotericin B - Comprehensive Patent Search

July 2014 $ 10 118

Bemiparin Sodium - Comprehensive Patent Search

July 2014 $ 10 118

Bevacizumab - Comprehensive Patent Search

July 2014 $ 10 118

Cefovecin (vet) - Comprehensive Patent Search

July 2014 $ 10 118

Cetuximab - Comprehensive Patent Search

July 2014 $ 10 118


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.